nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—CYP3A4—Temozolomide—malignant glioma	0.152	1	CbGbCtD
Trametinib—Ocular toxicity—Carmustine—malignant glioma	0.022	0.107	CcSEcCtD
Trametinib—Disease progression—Carmustine—malignant glioma	0.0137	0.0664	CcSEcCtD
Trametinib—MAP2K1—embryo—malignant glioma	0.00731	0.122	CbGeAlD
Trametinib—Haemorrhage intracranial—Temozolomide—malignant glioma	0.00702	0.0341	CcSEcCtD
Trametinib—MAP2K1—brainstem—malignant glioma	0.0067	0.112	CbGeAlD
Trametinib—MAP2K1—telencephalon—malignant glioma	0.00594	0.0991	CbGeAlD
Trametinib—Lymphopenia—Temozolomide—malignant glioma	0.00563	0.0274	CcSEcCtD
Trametinib—Cerebral haemorrhage—Carmustine—malignant glioma	0.00538	0.0262	CcSEcCtD
Trametinib—MAP2K2—telencephalon—malignant glioma	0.00523	0.0872	CbGeAlD
Trametinib—Cerebral haemorrhage—Temozolomide—malignant glioma	0.0052	0.0253	CcSEcCtD
Trametinib—Cyst—Carmustine—malignant glioma	0.00446	0.0217	CcSEcCtD
Trametinib—MAP2K1—spinal cord—malignant glioma	0.00416	0.0694	CbGeAlD
Trametinib—MAP2K2—medulla oblongata—malignant glioma	0.00411	0.0685	CbGeAlD
Trametinib—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00389	0.0189	CcSEcCtD
Trametinib—MAP2K2—midbrain—malignant glioma	0.00376	0.0626	CbGeAlD
Trametinib—MAP2K2—spinal cord—malignant glioma	0.00367	0.0611	CbGeAlD
Trametinib—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.0035	0.017	CcSEcCtD
Trametinib—MAP2K1—central nervous system—malignant glioma	0.00338	0.0563	CbGeAlD
Trametinib—MAP2K1—cerebellum—malignant glioma	0.0033	0.055	CbGeAlD
Trametinib—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.00317	0.0154	CcSEcCtD
Trametinib—MAP2K2—central nervous system—malignant glioma	0.00297	0.0496	CbGeAlD
Trametinib—MAP2K2—cerebellum—malignant glioma	0.00291	0.0485	CbGeAlD
Trametinib—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00288	0.014	CcSEcCtD
Trametinib—Neoplasm—Carmustine—malignant glioma	0.00269	0.0131	CcSEcCtD
Trametinib—MAP2K1—brain—malignant glioma	0.00268	0.0447	CbGeAlD
Trametinib—Dry eye—Temozolomide—malignant glioma	0.00266	0.0129	CcSEcCtD
Trametinib—Neoplasm—Temozolomide—malignant glioma	0.0026	0.0127	CcSEcCtD
Trametinib—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.0024	0.0117	CcSEcCtD
Trametinib—MAP2K2—brain—malignant glioma	0.00236	0.0394	CbGeAlD
Trametinib—Hyponatraemia—Carmustine—malignant glioma	0.00217	0.0106	CcSEcCtD
Trametinib—Hypokalaemia—Carmustine—malignant glioma	0.00197	0.00957	CcSEcCtD
Trametinib—Dehydration—Temozolomide—malignant glioma	0.00194	0.00945	CcSEcCtD
Trametinib—Dry skin—Temozolomide—malignant glioma	0.00192	0.00931	CcSEcCtD
Trametinib—Hypokalaemia—Temozolomide—malignant glioma	0.0019	0.00925	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.00188	0.00915	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00184	0.00896	CcSEcCtD
Trametinib—Neutropenia—Carmustine—malignant glioma	0.00175	0.0085	CcSEcCtD
Trametinib—Neutropenia—Temozolomide—malignant glioma	0.00169	0.00821	CcSEcCtD
Trametinib—Hyperglycaemia—Carmustine—malignant glioma	0.00169	0.0082	CcSEcCtD
Trametinib—Renal failure—Carmustine—malignant glioma	0.00164	0.00797	CcSEcCtD
Trametinib—Hyperglycaemia—Temozolomide—malignant glioma	0.00163	0.00792	CcSEcCtD
Trametinib—Stomatitis—Carmustine—malignant glioma	0.00163	0.0079	CcSEcCtD
Trametinib—Urinary tract infection—Carmustine—malignant glioma	0.00162	0.00788	CcSEcCtD
Trametinib—Infestation NOS—Temozolomide—malignant glioma	0.00161	0.00783	CcSEcCtD
Trametinib—Infestation—Temozolomide—malignant glioma	0.00161	0.00783	CcSEcCtD
Trametinib—Stomatitis—Temozolomide—malignant glioma	0.00157	0.00763	CcSEcCtD
Trametinib—Urinary tract infection—Temozolomide—malignant glioma	0.00157	0.00761	CcSEcCtD
Trametinib—Haemoglobin—Carmustine—malignant glioma	0.0015	0.00731	CcSEcCtD
Trametinib—Haemorrhage—Carmustine—malignant glioma	0.0015	0.00727	CcSEcCtD
Trametinib—Oedema peripheral—Carmustine—malignant glioma	0.00147	0.00717	CcSEcCtD
Trametinib—Connective tissue disorder—Carmustine—malignant glioma	0.00147	0.00715	CcSEcCtD
Trametinib—Haemoglobin—Temozolomide—malignant glioma	0.00145	0.00707	CcSEcCtD
Trametinib—Haemorrhage—Temozolomide—malignant glioma	0.00145	0.00703	CcSEcCtD
Trametinib—Urinary tract disorder—Temozolomide—malignant glioma	0.00143	0.00694	CcSEcCtD
Trametinib—Oedema peripheral—Temozolomide—malignant glioma	0.00142	0.00693	CcSEcCtD
Trametinib—Connective tissue disorder—Temozolomide—malignant glioma	0.00142	0.00691	CcSEcCtD
Trametinib—Urethral disorder—Temozolomide—malignant glioma	0.00142	0.00689	CcSEcCtD
Trametinib—Eye disorder—Carmustine—malignant glioma	0.0014	0.0068	CcSEcCtD
Trametinib—Eye disorder—Temozolomide—malignant glioma	0.00135	0.00657	CcSEcCtD
Trametinib—Cardiac disorder—Temozolomide—malignant glioma	0.00134	0.00652	CcSEcCtD
Trametinib—Arrhythmia—Carmustine—malignant glioma	0.00134	0.0065	CcSEcCtD
Trametinib—Angiopathy—Temozolomide—malignant glioma	0.00131	0.00638	CcSEcCtD
Trametinib—Mental disorder—Carmustine—malignant glioma	0.00131	0.00637	CcSEcCtD
Trametinib—Mediastinal disorder—Temozolomide—malignant glioma	0.0013	0.00634	CcSEcCtD
Trametinib—Erythema—Carmustine—malignant glioma	0.0013	0.00633	CcSEcCtD
Trametinib—Malnutrition—Carmustine—malignant glioma	0.0013	0.00633	CcSEcCtD
Trametinib—Chills—Temozolomide—malignant glioma	0.0013	0.00631	CcSEcCtD
Trametinib—Mental disorder—Temozolomide—malignant glioma	0.00127	0.00616	CcSEcCtD
Trametinib—Back pain—Carmustine—malignant glioma	0.00126	0.00613	CcSEcCtD
Trametinib—Erythema—Temozolomide—malignant glioma	0.00126	0.00612	CcSEcCtD
Trametinib—Malnutrition—Temozolomide—malignant glioma	0.00126	0.00612	CcSEcCtD
Trametinib—Dysgeusia—Temozolomide—malignant glioma	0.00123	0.00599	CcSEcCtD
Trametinib—Vision blurred—Carmustine—malignant glioma	0.00123	0.00597	CcSEcCtD
Trametinib—Back pain—Temozolomide—malignant glioma	0.00122	0.00592	CcSEcCtD
Trametinib—Anaemia—Carmustine—malignant glioma	0.0012	0.00585	CcSEcCtD
Trametinib—Vision blurred—Temozolomide—malignant glioma	0.00119	0.00577	CcSEcCtD
Trametinib—Leukopenia—Carmustine—malignant glioma	0.00117	0.00567	CcSEcCtD
Trametinib—Anaemia—Temozolomide—malignant glioma	0.00116	0.00566	CcSEcCtD
Trametinib—Leukopenia—Temozolomide—malignant glioma	0.00113	0.00548	CcSEcCtD
Trametinib—Hypertension—Carmustine—malignant glioma	0.00112	0.00547	CcSEcCtD
Trametinib—Myalgia—Carmustine—malignant glioma	0.00111	0.00539	CcSEcCtD
Trametinib—Cough—Temozolomide—malignant glioma	0.0011	0.00534	CcSEcCtD
Trametinib—Hypertension—Temozolomide—malignant glioma	0.00109	0.00528	CcSEcCtD
Trametinib—Arthralgia—Temozolomide—malignant glioma	0.00107	0.00521	CcSEcCtD
Trametinib—Myalgia—Temozolomide—malignant glioma	0.00107	0.00521	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00106	0.00517	CcSEcCtD
Trametinib—Oedema—Carmustine—malignant glioma	0.00106	0.00517	CcSEcCtD
Trametinib—Infection—Carmustine—malignant glioma	0.00106	0.00513	CcSEcCtD
Trametinib—Dry mouth—Temozolomide—malignant glioma	0.00105	0.0051	CcSEcCtD
Trametinib—Thrombocytopenia—Carmustine—malignant glioma	0.00104	0.00506	CcSEcCtD
Trametinib—Oedema—Temozolomide—malignant glioma	0.00103	0.00499	CcSEcCtD
Trametinib—Infection—Temozolomide—malignant glioma	0.00102	0.00496	CcSEcCtD
Trametinib—Nervous system disorder—Temozolomide—malignant glioma	0.00101	0.0049	CcSEcCtD
Trametinib—Thrombocytopenia—Temozolomide—malignant glioma	0.00101	0.00489	CcSEcCtD
Trametinib—Skin disorder—Temozolomide—malignant glioma	0.000998	0.00485	CcSEcCtD
Trametinib—Hyperhidrosis—Temozolomide—malignant glioma	0.000993	0.00483	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000969	0.00471	CcSEcCtD
Trametinib—Insomnia—Carmustine—malignant glioma	0.000962	0.00467	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000936	0.00455	CcSEcCtD
Trametinib—Insomnia—Temozolomide—malignant glioma	0.000929	0.00452	CcSEcCtD
Trametinib—Decreased appetite—Carmustine—malignant glioma	0.000924	0.00449	CcSEcCtD
Trametinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000918	0.00446	CcSEcCtD
Trametinib—Constipation—Carmustine—malignant glioma	0.000909	0.00442	CcSEcCtD
Trametinib—Decreased appetite—Temozolomide—malignant glioma	0.000893	0.00434	CcSEcCtD
Trametinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000887	0.00431	CcSEcCtD
Trametinib—Fatigue—Temozolomide—malignant glioma	0.000886	0.00431	CcSEcCtD
Trametinib—Constipation—Temozolomide—malignant glioma	0.000879	0.00427	CcSEcCtD
Trametinib—Gastrointestinal pain—Carmustine—malignant glioma	0.00087	0.00423	CcSEcCtD
Trametinib—Abdominal pain—Carmustine—malignant glioma	0.000841	0.00409	CcSEcCtD
Trametinib—Body temperature increased—Carmustine—malignant glioma	0.000841	0.00409	CcSEcCtD
Trametinib—Gastrointestinal pain—Temozolomide—malignant glioma	0.00084	0.00408	CcSEcCtD
Trametinib—CYP2C8—brain—malignant glioma	0.000818	0.0136	CbGeAlD
Trametinib—Abdominal pain—Temozolomide—malignant glioma	0.000812	0.00395	CcSEcCtD
Trametinib—Body temperature increased—Temozolomide—malignant glioma	0.000812	0.00395	CcSEcCtD
Trametinib—Asthenia—Carmustine—malignant glioma	0.000763	0.00371	CcSEcCtD
Trametinib—Asthenia—Temozolomide—malignant glioma	0.000737	0.00358	CcSEcCtD
Trametinib—Diarrhoea—Carmustine—malignant glioma	0.000728	0.00354	CcSEcCtD
Trametinib—Pruritus—Temozolomide—malignant glioma	0.000727	0.00353	CcSEcCtD
Trametinib—Dizziness—Carmustine—malignant glioma	0.000703	0.00342	CcSEcCtD
Trametinib—Diarrhoea—Temozolomide—malignant glioma	0.000703	0.00342	CcSEcCtD
Trametinib—CYP3A4—central nervous system—malignant glioma	0.000698	0.0116	CbGeAlD
Trametinib—Dizziness—Temozolomide—malignant glioma	0.00068	0.0033	CcSEcCtD
Trametinib—Vomiting—Carmustine—malignant glioma	0.000676	0.00329	CcSEcCtD
Trametinib—Rash—Carmustine—malignant glioma	0.00067	0.00326	CcSEcCtD
Trametinib—Dermatitis—Carmustine—malignant glioma	0.00067	0.00326	CcSEcCtD
Trametinib—Headache—Carmustine—malignant glioma	0.000666	0.00324	CcSEcCtD
Trametinib—Vomiting—Temozolomide—malignant glioma	0.000653	0.00318	CcSEcCtD
Trametinib—Rash—Temozolomide—malignant glioma	0.000648	0.00315	CcSEcCtD
Trametinib—Dermatitis—Temozolomide—malignant glioma	0.000647	0.00315	CcSEcCtD
Trametinib—Headache—Temozolomide—malignant glioma	0.000644	0.00313	CcSEcCtD
Trametinib—Nausea—Carmustine—malignant glioma	0.000632	0.00307	CcSEcCtD
Trametinib—Nausea—Temozolomide—malignant glioma	0.00061	0.00297	CcSEcCtD
Trametinib—CYP2C8—Metabolism—SPHK1—malignant glioma	3.14e-05	5.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BAD—malignant glioma	3.13e-05	5.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CD—malignant glioma	3.11e-05	5.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—BAD—malignant glioma	3.09e-05	5.3e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CYP2C18—malignant glioma	3.08e-05	5.29e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CAV1—malignant glioma	3.07e-05	5.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOTCH1—malignant glioma	3.06e-05	5.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CD80—malignant glioma	3.03e-05	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT2—malignant glioma	3.03e-05	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—malignant glioma	3.02e-05	5.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NTRK1—malignant glioma	3.02e-05	5.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP3—malignant glioma	3e-05	5.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CD80—malignant glioma	2.99e-05	5.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGF—malignant glioma	2.99e-05	5.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—malignant glioma	2.99e-05	5.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—malignant glioma	2.99e-05	5.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APC—malignant glioma	2.99e-05	5.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTPN11—malignant glioma	2.97e-05	5.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CDKN2B—malignant glioma	2.97e-05	5.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT2—malignant glioma	2.96e-05	5.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGF—malignant glioma	2.95e-05	5.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTPN11—malignant glioma	2.94e-05	5.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CD—malignant glioma	2.91e-05	5.01e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	2.9e-05	4.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—BAD—malignant glioma	2.89e-05	4.96e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTK2—malignant glioma	2.88e-05	4.96e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOTCH1—malignant glioma	2.86e-05	4.91e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CD—malignant glioma	2.84e-05	4.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HES1—malignant glioma	2.83e-05	4.87e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—malignant glioma	2.82e-05	4.85e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NCOR1—malignant glioma	2.82e-05	4.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—BRAF—malignant glioma	2.81e-05	4.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP3—malignant glioma	2.8e-05	4.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CD80—malignant glioma	2.8e-05	4.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—malignant glioma	2.8e-05	4.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APC—malignant glioma	2.8e-05	4.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—RAF1—malignant glioma	2.78e-05	4.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CDKN2B—malignant glioma	2.78e-05	4.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT2—malignant glioma	2.77e-05	4.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGF—malignant glioma	2.76e-05	4.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTPN11—malignant glioma	2.75e-05	4.72e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT2—malignant glioma	2.73e-05	4.7e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—FGF2—malignant glioma	2.72e-05	4.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CB—malignant glioma	2.71e-05	4.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTK2—malignant glioma	2.7e-05	4.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PDGFRA—malignant glioma	2.7e-05	4.64e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ASMT—malignant glioma	2.68e-05	4.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CD—malignant glioma	2.66e-05	4.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HES1—malignant glioma	2.65e-05	4.56e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	2.65e-05	4.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—malignant glioma	2.64e-05	4.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NCOR1—malignant glioma	2.64e-05	4.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—BRAF—malignant glioma	2.63e-05	4.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CD—malignant glioma	2.63e-05	4.51e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SPP1—malignant glioma	2.62e-05	4.5e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL8—malignant glioma	2.61e-05	4.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—RAF1—malignant glioma	2.6e-05	4.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—malignant glioma	2.6e-05	4.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—BCL2—malignant glioma	2.59e-05	4.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IFNG—malignant glioma	2.56e-05	4.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT2—malignant glioma	2.56e-05	4.4e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	2.55e-05	4.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—MDM2—malignant glioma	2.55e-05	4.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—FGF2—malignant glioma	2.55e-05	4.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—RAF1—malignant glioma	2.54e-05	4.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CB—malignant glioma	2.54e-05	4.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDGFRA—malignant glioma	2.52e-05	4.34e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BCAN—malignant glioma	2.52e-05	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—FGF2—malignant glioma	2.51e-05	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—ERBB2—malignant glioma	2.51e-05	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—IL2—malignant glioma	2.49e-05	4.28e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTT1—malignant glioma	2.49e-05	4.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TERT—malignant glioma	2.48e-05	4.27e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CB—malignant glioma	2.48e-05	4.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CD—malignant glioma	2.46e-05	4.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SPP1—malignant glioma	2.45e-05	4.21e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—malignant glioma	2.44e-05	4.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—malignant glioma	2.43e-05	4.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PDGFB—malignant glioma	2.42e-05	4.17e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2—malignant glioma	2.42e-05	4.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGFR1—malignant glioma	2.41e-05	4.14e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—malignant glioma	2.4e-05	4.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IFNG—malignant glioma	2.4e-05	4.12e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—MDM2—malignant glioma	2.38e-05	4.1e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—RAF1—malignant glioma	2.38e-05	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HIF1A—malignant glioma	2.37e-05	4.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MDM2—malignant glioma	2.35e-05	4.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—FGF2—malignant glioma	2.35e-05	4.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—ERBB2—malignant glioma	2.35e-05	4.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—RAF1—malignant glioma	2.34e-05	4.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS1—malignant glioma	2.33e-05	4.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—IL2—malignant glioma	2.33e-05	4.01e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	2.33e-05	4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—malignant glioma	2.32e-05	3.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CB—malignant glioma	2.32e-05	3.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—ERBB2—malignant glioma	2.32e-05	3.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CAV1—malignant glioma	2.3e-05	3.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CB—malignant glioma	2.29e-05	3.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL1B—malignant glioma	2.29e-05	3.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—IL2—malignant glioma	2.28e-05	3.91e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—malignant glioma	2.27e-05	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—malignant glioma	2.27e-05	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PDGFB—malignant glioma	2.27e-05	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGFR1—malignant glioma	2.26e-05	3.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—malignant glioma	2.25e-05	3.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIF1A—malignant glioma	2.22e-05	3.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MDM2—malignant glioma	2.2e-05	3.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—RAF1—malignant glioma	2.19e-05	3.77e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FN1—malignant glioma	2.19e-05	3.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—F2—malignant glioma	2.19e-05	3.76e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—ERBB2—malignant glioma	2.17e-05	3.73e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—BCHE—malignant glioma	2.17e-05	3.73e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BAD—malignant glioma	2.16e-05	3.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CAV1—malignant glioma	2.15e-05	3.69e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC5A5—malignant glioma	2.14e-05	3.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—malignant glioma	2.14e-05	3.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—malignant glioma	2.14e-05	3.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH1—malignant glioma	2.14e-05	3.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL1B—malignant glioma	2.14e-05	3.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—IL2—malignant glioma	2.13e-05	3.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—malignant glioma	2.12e-05	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—malignant glioma	2.12e-05	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—malignant glioma	2.12e-05	3.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CD80—malignant glioma	2.1e-05	3.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APC—malignant glioma	2.09e-05	3.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—malignant glioma	2.09e-05	3.6e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGF—malignant glioma	2.07e-05	3.55e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTPN11—malignant glioma	2.06e-05	3.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—F2—malignant glioma	2.05e-05	3.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FN1—malignant glioma	2.05e-05	3.52e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH2—malignant glioma	2.03e-05	3.48e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	2.03e-05	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BAD—malignant glioma	2.02e-05	3.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	2.01e-05	3.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—malignant glioma	2e-05	3.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—malignant glioma	2e-05	3.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—malignant glioma	1.98e-05	3.41e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—malignant glioma	1.98e-05	3.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—BRAF—malignant glioma	1.97e-05	3.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CD80—malignant glioma	1.96e-05	3.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—malignant glioma	1.96e-05	3.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APC—malignant glioma	1.96e-05	3.36e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGF—malignant glioma	1.93e-05	3.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTPN11—malignant glioma	1.92e-05	3.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—malignant glioma	1.92e-05	3.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT2—malignant glioma	1.91e-05	3.29e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2B6—malignant glioma	1.91e-05	3.28e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—malignant glioma	1.91e-05	3.28e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—malignant glioma	1.85e-05	3.18e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—BRAF—malignant glioma	1.84e-05	3.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—malignant glioma	1.84e-05	3.16e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—malignant glioma	1.8e-05	3.09e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—malignant glioma	1.79e-05	3.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT2—malignant glioma	1.79e-05	3.08e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—malignant glioma	1.78e-05	3.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—malignant glioma	1.77e-05	3.04e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—FGF2—malignant glioma	1.76e-05	3.03e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.75e-05	3.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—IDH1—malignant glioma	1.74e-05	3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—malignant glioma	1.74e-05	2.99e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GSTP1—malignant glioma	1.73e-05	2.97e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—malignant glioma	1.72e-05	2.96e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SPHK1—malignant glioma	1.69e-05	2.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—malignant glioma	1.68e-05	2.9e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAT—malignant glioma	1.68e-05	2.89e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—malignant glioma	1.66e-05	2.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—malignant glioma	1.65e-05	2.84e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CYP2C18—malignant glioma	1.65e-05	2.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MDM2—malignant glioma	1.65e-05	2.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—FGF2—malignant glioma	1.65e-05	2.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—malignant glioma	1.65e-05	2.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—malignant glioma	1.64e-05	2.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—RAF1—malignant glioma	1.64e-05	2.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—malignant glioma	1.63e-05	2.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—ERBB2—malignant glioma	1.62e-05	2.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—malignant glioma	1.61e-05	2.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—malignant glioma	1.6e-05	2.76e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—NCOR1—malignant glioma	1.59e-05	2.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—malignant glioma	1.55e-05	2.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MDM2—malignant glioma	1.54e-05	2.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—malignant glioma	1.54e-05	2.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—malignant glioma	1.54e-05	2.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—malignant glioma	1.54e-05	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—RAF1—malignant glioma	1.54e-05	2.64e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—ERBB2—malignant glioma	1.52e-05	2.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—malignant glioma	1.52e-05	2.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—malignant glioma	1.51e-05	2.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—malignant glioma	1.5e-05	2.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—malignant glioma	1.5e-05	2.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—malignant glioma	1.47e-05	2.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—IL2—malignant glioma	1.47e-05	2.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—malignant glioma	1.44e-05	2.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—malignant glioma	1.42e-05	2.44e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—malignant glioma	1.41e-05	2.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—malignant glioma	1.4e-05	2.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—malignant glioma	1.39e-05	2.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—malignant glioma	1.39e-05	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—malignant glioma	1.38e-05	2.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—IL2—malignant glioma	1.38e-05	2.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—malignant glioma	1.35e-05	2.32e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTT1—malignant glioma	1.34e-05	2.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—malignant glioma	1.31e-05	2.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—malignant glioma	1.3e-05	2.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—malignant glioma	1.3e-05	2.23e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CAV1—malignant glioma	1.29e-05	2.22e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—malignant glioma	1.26e-05	2.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS1—malignant glioma	1.25e-05	2.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—malignant glioma	1.25e-05	2.15e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—malignant glioma	1.24e-05	2.13e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.24e-05	2.12e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—malignant glioma	1.23e-05	2.12e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—malignant glioma	1.18e-05	2.02e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—malignant glioma	1.17e-05	2.01e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—BCHE—malignant glioma	1.16e-05	2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—malignant glioma	1.16e-05	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—malignant glioma	1.16e-05	1.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—malignant glioma	1.15e-05	1.98e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	1.15e-05	1.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—malignant glioma	1.14e-05	1.96e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—malignant glioma	1.14e-05	1.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—malignant glioma	1.13e-05	1.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—malignant glioma	1.08e-05	1.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—malignant glioma	1.07e-05	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—malignant glioma	1.06e-05	1.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—malignant glioma	1.05e-05	1.81e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—malignant glioma	1.04e-05	1.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—malignant glioma	9.95e-06	1.71e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—malignant glioma	9.77e-06	1.68e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—malignant glioma	9.45e-06	1.62e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GSTP1—malignant glioma	9.27e-06	1.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—malignant glioma	9.14e-06	1.57e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—malignant glioma	9.03e-06	1.55e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAT—malignant glioma	9.02e-06	1.55e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—malignant glioma	8.94e-06	1.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—malignant glioma	8.85e-06	1.52e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—NCOR1—malignant glioma	8.52e-06	1.46e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—malignant glioma	7.98e-06	1.37e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—malignant glioma	7.8e-06	1.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—malignant glioma	7.47e-06	1.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CAV1—malignant glioma	6.94e-06	1.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	6.32e-06	1.09e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—malignant glioma	6.1e-06	1.05e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	5.56e-06	9.55e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—malignant glioma	5.5e-06	9.46e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	4.85e-06	8.33e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—malignant glioma	4.8e-06	8.25e-06	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—malignant glioma	4.5e-06	7.73e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—malignant glioma	4.19e-06	7.2e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	2.95e-06	5.08e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—malignant glioma	2.41e-06	4.15e-06	CbGpPWpGaD
